골수증식성 질환(MPD) 치료제/치료 시장 규모 : 질환 유형별, 약제 클래스별, 투여 경로별, 최종 용도별, 예측(2024-2032년)

Myeloproliferative disorders drugs/treatment market is estimated to register 3.2% CAGR between 2024 and 2032, owing to the increasing prevalence of myeloproliferative disorders, such as polycythemia vera, essential thrombocythemia, and myelofibrosis. As per AACR (American Association for Cancer Research), an estimated 13,000 people were living with myelofibrosis in the U.S. These disorders are characterized by the abnormal production of blood cells in the bone marrow, leading to various complications. Consequently, there is a growing demand for effective drugs and treatments to manage symptoms, improve quality of life, and prolong survival among patients. Additionally, advancements in medical research and drug development have led to the discovery of novel therapies targeting specific molecular pathways involved in myeloproliferative disorders.

With aging population worldwide, the prevalence of these conditions is expected to rise, further driving the demand for drugs and treatments. Moreover, the awareness among healthcare professionals and patients about early diagnosis and prompt intervention is increasing. The strong focus on timely diagnosis as it allows the initiation of appropriate treatments to help manage symptoms, prevent disease progression, and improve patient outcomes will favor the market growth.

The myeloproliferative disorders drugs/treatment industry is classified into disorder type, drug class, route of administration, end-use and region.

Based on route of administration, the market value from the oral segment is slated to grow at 3.1% CAGR during 2024-2032, as they offer convenience and flexibility for patients, allowing them to administer treatments at home without the need for frequent clinic visits. This enhanced patient convenience leads to better treatment adherence and improved quality of life. Additionally, advancements in pharmaceutical research have resulted in the development of oral drugs targeting specific molecular pathways involved in myeloproliferative disorders for offering more effective and targeted treatment options.

In terms of end-use, the myeloproliferative disorders drugs/treatment market from the specialty clinics segment will record 3.3% growth rate through 2032. This is driven by their specialized expertise and comprehensive care in managing complex hematologic conditions like myeloproliferative disorders. These clinics provide tailored treatment plans, close monitoring, and access to advanced therapies for ensuring optimal management of the disease. Additionally, specialty clinics often serve as referral centers, attracting patients seeking specialized care from a wide geographic area. Moreover, collaborations between specialty clinics and pharmaceutical companies for facilitating clinical trials and the development of innovative therapies are further driving the market growth.

Europe myeloproliferative disorders drug treatment market size may expand substantially at 3.3% CAGR up to 2032, attributed to the advancements in medical research and drug development, particularly in countries with robust healthcare systems like Germany and the U.K. Furthermore, the presence of specialized healthcare facilities and academic centers focusing on hematologic diseases in Europe will foster collaboration between clinicians and researchers, leading to the development of tailored therapies.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Forecast parameters
• 1.4 Data collection
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of myeloproliferative diseases globally
    • 3.2.1.2 Increasing R&D efforts to develop new drugs
    • 3.2.1.3 Growing advancement in targeted therapies
    • 3.2.1.4 Increasing geriatric population
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited treatment options
    • 3.2.2.2 High cost of treatment
    • 3.2.2.3 Adverse effects associated with the drugs
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players,
• 4.4 Competitive positioning matrix
• 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Disorder Type, 2018-2032 ($ Million)

• 5.1 Key trends
• 5.2 Philadelphia chromosome-positive (Ph+) CML
• 5.3 Philadelphia chromosome-negative (Ph-) MPNs
  • 5.3.1 Polycythemia vera
  • 5.3.2 Essential thrombocythemia
  • 5.3.3 Myelofibrosis
• 5.4 Other disorder types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2018-2032 ($ Million)

• 6.1 Key trends
• 6.2 Tyrosine kinase inhibitors
• 6.3 Janus kinase inhibitors
• 6.4 Hydroxyurea
• 6.5 Other drug classes

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018-2032 ($ Million)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable

Chapter 8 Market Estimates and Forecast, By End-Use, 2018-2032 ($ Million)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Specialty clinics
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

• 9.1 Key trends, by region
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 AbbVie Inc.
• 10.2 Bristol-Myers Squibb Company
• 10.3 Eli Lilly and Company
• 10.4 GlaxoSmithKline plc (GSK)
• 10.5 GL Pharma GmbH
• 10.6 Incyte Corporation
• 10.7 Janssen Biotech, Inc. (Johnson & Johnson)
• 10.8 MorphoSys AG
• 10.9 Mylan N.V. (Viatris)
• 10.10 Novartis Pharmaceuticals Corporation (Novartis AG)
• 10.11 Takeda Pharmaceutical Company Limited
• 10.12 Teva Pharmaceutical Industries Ltd.